返回 
加入收藏
斯鲁利单抗一线治疗小细胞肺癌的快速卫生技术评估
x
请在关注微信后，向客服人员索取文件
| 篇名： | 斯鲁利单抗一线治疗小细胞肺癌的快速卫生技术评估 |
| TITLE： | Rapid health technology assessment of serplulimab in the first-line treatment of small-cell lung cancer |
| 摘要： | 目的 评价斯鲁利单抗一线治疗小细胞肺癌（SCLC）的有效性、安全性和经济性，为医疗机构药物遴选提供循证依据。方法采用快速卫生技术评估方法，系统检索PubMed、CochraneLibrary、Embase、中国知网、万方数据、维普网以及国内外卫生技术评估机构官方网站，检索时限为建库开始至2024年10月，由2名评价者根据纳入和排除标准独立筛选文献并评估文献质量后，进行定性分析。结果共纳入13篇系统评价/Meta分析和9篇经济学研究，文献质量总体良好。有效性方面，与单纯化疗相比，斯鲁利单抗联合化疗可显著改善SCLC患者的无进展生存期、总生存期和客观缓解率。安全性方面，斯鲁利单抗联合化疗方案治疗SCLC导致的3级及以上不良事件发生率与单纯化疗相比无明显差异，显示出良好的安全性；与其他免疫抑制剂的联合疗法相比，其不良事件的发生率也较低。经济性方面，相比于单纯化疗方案，斯鲁利单抗联合化疗方案不具有经济性，可能与斯鲁利单抗价格过高有关。结论斯鲁利单抗一线治疗SCLC的有效性、安全性较好，但经济性无明显优势。 |
| ABSTRACT： | OBJECTIVE To evaluate the efficacy， safety and cost-effectiveness of serplulimab as a first-line treatment of small- cell lung cancer （SCLC）， and provide an evidence-based basis for drug selection in hospitals. METHODS Rapid health technology assessment was adopted； PubMed， Cochrane Library， Embase， CNKI， Wanfang， VIP and official websites of domestic and international health technology assessment agencies were systematically searched from the inception to Oct. 2024. Two reviewers independently screened the literature， assessed the quality of included studies and carried out the qualitative analysis according to the inclusion and exclusion criteria. RESULTS A total of 13 systematic reviews/meta-analyses and 9 economic studies were included， and the literature quality was generally good. In terms of effectiveness， compared with chemotherapy alone， serplulimab combined with chemotherapy significantly improved progression-free survival， overall survival， and objective response rate in patients with SCLC. In terms of safety， serplulimab combined with chemotherapy showed no significant difference in the incidence of ≥3 grade adverse events compared with chemotherapy alone in the treatment of SCLC， indicating a good safety profile； compared with combination therapies involving other immunosuppressive agents， the incidence rate of adverse events was also lower. In terms of cost-effectiveness， compared with chemotherapy alone， serplulimab combined with chemotherapy is not cost- effective， which may be related to the high price of serplulimab. CONCLUSIONS Serplulimab is effective and safe in the treatment of SCLC， but has no obvious advantage in terms of cost-effectiveness. |
| 期刊： | 2025年第36卷第11期 |
| 作者： | 侯奕冰；康朔；公元；王晓晖；聂颖；刘焕龙 |
| AUTHORS： | HOU Yibing，KANG Shuo，GONG Yuan，WANG Xiaohui，NIE Ying，LIU Huanlong |
| 关键字： | 斯鲁利单抗；小细胞肺癌；有效性；安全性；经济性；快速卫生技术评估 |
| KEYWORDS： | serplulimab； small-cell lung cancer； effectiveness； safety； cost-effectiveness； rapid health technology assessment |
| 阅读数： | 16 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
